REVTORPYK™: A New FDA Approval for Gedatolisib/HPBCD composition
A new chapter in targeted cancer therapy On July 14, 2026, the U.S. FDA approved REVTORPYK™ (gedatolisib), developed by Celcuity,
Tag: combination
METHYL-CYCLODEXTRIN FOR USE IN TREATING ENVELOPED VIRUS INFECTIONS SUCH AS SARS-CoV-2
The patent application (1) with priority date of 09. March 2020 claims that methyl bCD preferably with DS 0.7 (Crysmeb)